Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Misop Han

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
Cancer|December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
The Journal of Urology|June 16, 2009
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomyLionel L Bañez, Leon Sun, Bruce J Trock, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
International Journal of Surgical Pathology|April 9, 2013
Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancerNilda González-Roibón, Jeong S Han, Stephen Lee, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 4, 2012
Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrencePaul J Dluzniewski, Ming-Hsi Wang, Siqun Lilly Zheng, et al.
JAMA Network Open|April 11, 2023
Trainee Physician Milestone Ratings and Patient Complaints in Early Posttraining PracticeMisop Han, Stanley J Hamstra, Sean O Hogan, et al.
BJU International|July 2, 2024
Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomySanaz Nourmohammadi Abadchi, Daniela C Salles, Cynthia Flannery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsTamara L Lotan, Bora Gurel, Siobhan Sutcliffe, et al.
The Journal of Urology|May 31, 2016
SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy CohortMichael H Johnson, Ashley E Ross, Mohammed Alshalalfa, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
Cancer|December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
The Journal of Urology|June 16, 2009
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomyLionel L Bañez, Leon Sun, Bruce J Trock, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
International Journal of Surgical Pathology|April 9, 2013
Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancerNilda González-Roibón, Jeong S Han, Stephen Lee, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 4, 2012
Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrencePaul J Dluzniewski, Ming-Hsi Wang, Siqun Lilly Zheng, et al.
JAMA Network Open|April 11, 2023
Trainee Physician Milestone Ratings and Patient Complaints in Early Posttraining PracticeMisop Han, Stanley J Hamstra, Sean O Hogan, et al.
BJU International|July 2, 2024
Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomySanaz Nourmohammadi Abadchi, Daniela C Salles, Cynthia Flannery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patientsTamara L Lotan, Bora Gurel, Siobhan Sutcliffe, et al.
The Journal of Urology|May 31, 2016
SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy CohortMichael H Johnson, Ashley E Ross, Mohammed Alshalalfa, et al.
Pageof 20